Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Running

SakuraBead SakuraBead - pain agnostic treatment for everyone

Coordinator
Crannmed Ltd, Ireland
Runs
1 June 2026 to 31 May 2028
Status
Running
EU funding
€2.4m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101297521

What the project is doing

In the project's own words, from its summary on CORDIS.

At CrannMed we are developing resorbable embolic microspheres to unlock the growing potential of vascular embolization. We call this technology SakuraBead. Our new approach to the treatment of chronic MSK pain is based on a recent unifying understanding of the mechanism of the disease. Previously chronic MSK pain was considered to be a wear and tear disease, but recent research suggests that the underlying root cause is a self-propagating chronic inflammatory process.

This inflammatory process is characterized by the presence of neo-vessels in the tissue surrounding the site of pain. Deactivation of these neo-vessels via embolization treats the mechanism of action of the disease and disrupts the pain pathway promising years of pain free living. Effectively, our technology can turn off the mechanism of pain by interrupting the inflammatory process that sustains it. The technology has been validated in a human clinical studies focused on knee osteoarthritis which resulted in significant and long term pain relief.

SakuraBead will be the world’s first embolic that can be delivered by direct injection in an outpatient setting. Should the technology achieve its full potential it can replace upwards of 50 million steroid injections per year. Clinical validation of the technology in expanded anatomical locations is a large part of the project.

Who is involved

OrganisationCityCountryRole
Crannmed LtdGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI